TSX Venture Exchange: NVC
June 14, 2012
/PRNewswire/ - Neovasc Inc.
(TSXV: NVC), a developer of novel technologies to treat vascular disease, today announced that the company will present at the Bloom Burton & Co. Healthcare Investor Conference on
June 21, 2012
9:30 am EDT
. The conference will be held at the
Board of Trade in
. Neovasc management will provide an overview of recent company developments.
A copy of the corporate presentation that includes the material Neovasc will be presenting will be available on the Neovasc website at
About the Bloom Burton & Co. Healthcare Investor Conference
Bloom Burton & Co. is
largest and most active healthcare-specialized investment banking group. The Healthcare Investor Conference brings together U.S., Canadian and European investors who are interested in the latest developments in the Canadian healthcare sector. Attendees will have an opportunity to obtain corporate updates from the premier Canadian public and private companies through presentations and break-out Q&A sessions. For more information, visit
About Neovasc Inc.
Neovasc Inc. is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™ for the treatment of refractory angina, the Tiara™ technology in development for the transcatheter treatment of mitral valve disease and a line of advanced biological tissue products that are used as key components in a variety of third-party medical products, such as vascular surgical patches and transcatheter heart valves. For more information, visit:
SOURCE Neovasc Inc.